Every day, hospitals throughout the U.S. transfuse blood or blood components, such as platelets, to save the lives of people who are in car crashes, and victims of fires and other emergencies.

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about prostate cancer awareness and the FDA’s approval of a new pain medication. He also explains a study that ...

Unnecessarily high doses not only increase risk of complications and adverse effects associated with the drug but increase hospital costs. Certainly, more studies will be required to define the best ...

The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing pain signals from reaching the brain. The approval marks the first new ...

The U.S. Food and Drug Administration signed off Thursday on the first new type of pain reliever ... taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts.

TLX007-CDx, a PSMA-PET imaging agent for prostate cancer, may offer an extended distribution profile compared to current agents, with an FDA decision expected by March 24, 2025. Gepotidacin, a ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...